



Dear WIPO Re:Search Members and Friends,

Happy New Year!

While it may only be January, 2019 is shaping up to be an impactful year, with many WIPO Re:Search projects advancing through research and product development milestones. Building on the success of 2018, we look forward to establishing new and promising R&D collaborations across our growing network of Members this year. Keep an eye out for our 2018 WIPO Re:Search Partnership Hub Annual Report in February.

Through the [WIPO Re:Search Australian Government-Funded Fellowship Program](#), BVGH is coordinating the placement of five additional scientists from East Africa and the Indo-Pacific region at advanced research institutions and companies – including the **Burnet Institute**, the **Griffith Institute for Drug Discovery**, **Johnson & Johnson**, **PATH**, **University of California, San Diego**, and **University of Melbourne**.

Together with our partner WIPO, we will continue to highlight the Consortium's successes and impacts through the new [WIPO Re:Search Resource Platform](#), this newsletter, other online and print materials, international presentations, and social media. BVGH will also begin development of our third WIPO Re:Search Partnership Storybook. View the last Storybook [here](#).

As we dive into the New Year, BVGH thanks you for your continued support and participation in WIPO Re:Search. As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

*Sincerely,  
Jennifer Dent  
President, BVGH*



---

## WIPO Re:Search Statistics



Click [here](#) for a list of WIPO Re:Search Members.

Click [here](#) for a list of WIPO Re:Search collaborations.

---

## Cornerstones of Collaboration

### [Johnson & Johnson Shares Compounds to Aid in Malaria Research](#)



**Johnson & Johnson** has provided Drs. Audrey Odom John and Paul Hruz at **Washington University, St. Louis** with its Jump-stARter library to screen against *P. falciparum*, the most deadly species of malaria parasite. Drs. Odom John and Hruz have developed a novel platform to selectively screen compounds' ability to inhibit parasite glucose transport.

---

## BVGH FundFinder Featured Award

### [NIH U.S.-Brazil Collaborative Biomedical Research Program](#)

The purpose of this funding opportunity is to promote collaborative biomedical research between the United States (U.S.) and Brazil. Research areas supported under this program include allergy, immunology, and infectious diseases, including Chagas disease, dengue, leishmaniasis, leprosy, malaria, schistosomiasis, soil-transmitted helminthiasis, tuberculosis, and HIV/AIDS and its co-morbidities; neurological disorders and stroke; and environmental health sciences.

- **Funding Amount:** Maximum of \$175,000 direct costs per year - *Maximum project period is 4 years*
- **Funder:** National Institutes of Health (NIH)
- **Deadline:** Letters of intent due February 8, 2019
- **Eligibility:** Partnerships between U.S. and Brazilian institutions that address public health topics of mutual benefit to both nations

## Additional Funding Opportunities

- [AREF/EDCTP Preparatory Fellowships](#) – Deadline: February 1, 2019
- [TDR Clinical Research and Development Fellowships](#) – Deadline: March 7, 2019
- [Japan Society for the Promotion of Science \(JSPS\) Research Fellowships in Japan](#) – Deadline: March 15, 2019
- [Neglected Tropical Diseases Support Center: Operational Research on "Endgame" Challenges](#) – No deadline specified

For more information about BVGH FundFinder, please email [Cathy Manner](#).



---

## Highlighted Contributions

### Leprosy

Affecting the skin, peripheral nerves, mucosa of the upper respiratory tract, and eyes, leprosy is an infection caused by the bacteria *Mycobacterium leprae*. If left untreated, the disease can result in progressive and permanent damage to the skin, nerves, limbs, and eyes. Over 200,000 new cases are diagnosed each year, mostly in Brazil, India, and other areas with warm climates.

This Snapshot highlights the following compounds with repurposing potential against *Mycobacterium leprae*:

- [Dihydrofolate reductase \(DHFR\) inhibitors](#)
- [HMG-CoA reductase inhibitors](#)
- [Phosphoinositide 3-kinase \(PI3K\) inhibitors](#)
- [Squalene synthase inhibitors](#)
- [Tyrosine kinase inhibitors](#)

For more information or to discuss potential collaborations involving these compounds, please contact [Cathy Manner](#).

---

## Upcoming Global Health Events

Dates	Event Name	Location
March 8-10, 2019	<a href="#">Consortium of Universities for Global Health (CUGH) Annual Conference</a>	Chicago, IL, USA
March 23-29, 2019	Gordon Research <a href="#">Seminar</a> and <a href="#">Conference</a> : From Innovation in Tropical Infectious Diseases to Global Health Solutions	Galveston, TX, USA
April 13-16, 2019	<a href="#">European Congress of Clinical Microbiology and Infectious Diseases</a>	Amsterdam, Netherlands
April 14-17, 2019	<a href="#">World Vaccine Congress Washington</a>	Washington, DC, USA
May 12-15, 2019	<a href="#">Wellcome Centre for Anti-Infectives Research (WCAIR) Conference on Innovative Drug Discovery and Development</a>	Dundee, UK



\*\*



\*Known as EMD in the US and Canada | \*\*Known as Merck & Co., Inc. in the US and Canada



Copyright © 2019 BVGH, All rights reserved.

Mailing address: 2101 4th Avenue, Suite 1950, Seattle, WA 98121